^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

IL6-L

i
Other names: IL6, BSF2, HGF, HSF, IFNB2, IL-6, Interleukin 6
Entrez ID:
Related biomarkers:
7d
The relationship between hematologic malignancies on male hypogonadism: a scoping review. (PubMed, Sex Med Rev)
There is a relationship between hematologic malignancies and hypogonadism, which is likely multifactorial. In this review we established that the most plausible factors are related to the secondary effects of gonadotoxic treatments and/or systemic inflammatory responses to the diseases.
Review • Journal
|
IL6 (Interleukin 6)
|
IL6-L
26d
Preliminary study on the effect of Echinococcus multilocaris on phenotypic transformations of glucose metabolism and polarization types in macrophages (PubMed, Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi)
Treatment of E. multilocularis CF or PSC mainly causes polarization of BMDM into M2 macrophages, and phenotypic transformation of glucose metabolism into high-energy and high-glycolytic metabolism, and affects inflammatory responses in BMDM.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CSF1 (Colony stimulating factor 1) • IL10 (Interleukin 10) • CCL2 (Chemokine (C-C motif) ligand 2) • TGFB1 (Transforming Growth Factor Beta 1) • CCL22 (C-C Motif Chemokine Ligand 22) • GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • SLC2A1 (Solute Carrier Family 2 Member 1)
|
IL6-L • IL6 expression
30d
Harvesting the Power of Green Synthesis: Gold Nanoparticles Tailored for Prostate Cancer Therapy. (PubMed, Int J Mol Sci)
Crucially, these nanoparticles demonstrate negligible effects on HPEpiC cells while significantly impacting PC3 cells, resulting in reduced viability, migration, and lower IL-6 levels. This research lays the groundwork for the development of more specialized, economical, and ecologically friendly treatment modalities.
Journal
|
IL6 (Interleukin 6)
|
IL6-L
2ms
Association of pro-inflammatory cytokines, adipokines and hepatokine with incident diabetes in India: a nested case-control study within CARRS cohort. (PubMed, Acta Diabetol)
Higher TNF-α and MCP-1 levels and lower IL-6 were associated with higher risk of developing diabetes. Better understanding and potential methods of addressing these biomarkers, especially in relation to family history, are needed to address diabetes in South Asians.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CCL2 (Chemokine (C-C motif) ligand 2) • CRP (C-reactive protein) • LEP (Leptin)
|
IL6-L
2ms
Circular RNA Cbl proto-oncogene B (circCBLB) inhibits proliferation, promotes apoptosis, and increases anti-inflammatory cytokine levels of fibroblast-like synoviocytes in rheumatoid arthritis (PubMed, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi)
Conclusion circCBLB inhibits the viability of RA-FLS, increases apoptosis rate, prolongs the cell cycle, reduces colony formation ability, increases antiinflammatory cytokines, and decreases proinflammatory cytokines. In contrast, miR-486-5p has opposite regulatory effects on circCBLB and can partially reverse and offset the effects of circCBLB.
Journal • Circular RNA
|
IL6 (Interleukin 6) • IL10 (Interleukin 10) • IL4 (Interleukin 4) • MIR486-1 (MicroRNA 486-1)
|
IL6-L • IL10 elevation
3ms
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer. (PubMed, Target Oncol)
Low baseline plasma concentrations of HGF and IL-8 may predict better DCR and PFS in patients with mCRC receiving FTD/TPI plus bevacizumab, however further studies are warranted.
P2/3 data • Journal • Metastases
|
IL6 (Interleukin 6) • HGF (Hepatocyte growth factor) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • SPP1 (Secreted Phosphoprotein 1) • THBS2 (Thrombospondin 2)
|
HGF-L • IL6-L • CXCL8-L • SPP1-L
|
Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)
3ms
Adaptive immune cells are necessary for SARS-CoV-2-induced pathology. (PubMed, Sci Adv)
Mice lacking αβ T cells also had less severe weight loss, but adoptive transfer of T and B cells into rag mice did not significantly change the response. Collectively, these findings suggest that while adaptive immune cells are important for clearing SARS-CoV-2 infection, this comes at the expense of increased inflammation and pathology.
Journal • Immune cell
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
|
IL6-L
4ms
Mesenteric adipose tissue B lymphocytes promote intestinal injury in severe acute pancreatitis by mediating enteric pyroptosis. (PubMed, Hepatobiliary Pancreat Dis Int)
In SAP, MAT B lymphocytes aggravated local inflammation, and promoted the injury to the intestine through the enteric pyroptotic pathway.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • NLRP3 (NLR Family Pyrin Domain Containing 3) • TJP1 (Tight Junction Protein 1) • OCLN (Occludin)
|
IL6-L • IL6 expression
4ms
EX103, a Novel CD20xCD3 Bispecific Antibody, Showed a Favorable Safety and Potent Single-Agent Antitumor Activity in Heavily Pretreated Relapsed/Refractory Patients with B-Cell Non-Hodgkin Lymphoma (ASH 2023)
Furthermore, EX103 demonstrates promising efficacy in heavily pretreated patients with R/R B-NHL, including some who have previously failed CAR-T treatment. The safety and efficacy of EX103 will be further evaluated in an ongoing clinical study.
Clinical
|
CD20 (Membrane Spanning 4-Domains A1) • IL6 (Interleukin 6)
|
IL6-L
|
EX103
4ms
Association between IL-6 and prognosis of gastric cancer: a retrospective study. (PubMed, Therap Adv Gastroenterol)
IL-6, N stage, and T stage are independent prognostic factors, and the new survival prognostic model consisting of the above three indicators is better than the classical TNM staging system. This study is a retrospective study, which does not require clinical registration.
Retrospective data • Journal
|
IL6 (Interleukin 6)
|
IL6-L • IL6 expression
4ms
Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma. (PubMed, Front Pharmacol)
We enrolled 57 patients with aUC who were treated with the anti-programmed cell death protein 1 (PD-1) antibody pembrolizumab after the failure of platinum-based chemotherapy between February 2018 and December 2020...Notably, using correlation and principal component analysis, factors significantly associated with clinical outcomes were broadly classified into three groups exhibiting similar expression patterns. Measuring plasma levels of soluble immune mediators, such as IL-6, IL-8, sTNF-R1, IFNγ, and IL-12 (p40), could be recommended for predicting prognosis and irAEs in ICI-treated patients with aUC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • TNFRSF1A (TNF Receptor Superfamily Member 1A)
|
IL6-L
|
Keytruda (pembrolizumab)
5ms
Linkage between Psychological Factors and Response to Immune Checkpoint Inhibitor Therapy: A Preliminary Study. (PubMed, Cells)
sPD-1 was not associated with psychological measures. This preliminary study found for the first time that some psychological measures could be linked to responses to cancer treatment, possibly via pro-inflammatory cytokines and sCTLA-4.
Journal • Checkpoint inhibition • IO biomarker
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
|
IL6-L
6ms
IL-6 as prognostic factor in adjuvant or metastatic skin cancer patients treated with immunotherapy – a deep biomarker analysis (SITC 2023)
We included pts with unresectable/metastatic cutaneous squamous cell carcinoma (cSCC) treated with cemiplimab (n=47); pts with resected stage III/IV melanoma (n=98) treated with anti-PD1; pts with metastatic melanoma treated with anti-PD1 (n=139), combo ipi+nivo (n=65) and ipilimumab alone (n=37). Furthermore, IL-6 is associated to higher expression of genes relate to cell cycle, proliferation and metastasis. Further investigations are needed to get additional information.
Clinical • PD(L)-1 Biomarker • IO biomarker • Metastases
|
EGFR (Epidermal growth factor receptor) • IL6 (Interleukin 6)
|
IL6-L • IL6 expression
|
Yervoy (ipilimumab) • Libtayo (cemiplimab-rwlc)
6ms
Postoperative inflammatory response in colorectal cancer surgery: a meta-analysis. (PubMed, Int J Colorectal Dis)
The findings of this study indicate a superior inflammatory profile for laparoscopic surgery compared to an open approach for colorectal cancer surgery. For future research, it would be worthwhile to conduct a randomized controlled trial to compare the postoperative inflammatory response and related clinical outcomes between minimally invasive surgical approaches, including laparoscopic and robot-assisted surgery.
Retrospective data • Review • Journal • Surgery
|
IL6 (Interleukin 6) • CRP (C-reactive protein)
|
IL6-L
6ms
Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin. (PubMed, Breast Cancer Res Treat)
Baseline IL-6 is an important prognostic factor in patients with MBC treated with eribulin. Our results show that high IL-6 is associated with higher levels of MDSCs which suppress anti-tumor immunity, such as CD8 cells. It appears that eribulin is not particularly effective in patients with high IL-6 due to a poor tumor immune microenvironment.
Journal • Metastases
|
CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • CD4 (CD4 Molecule)
|
IL6-L
|
Halaven (eribulin mesylate)
7ms
Associations of Adherence to the 2018 World Cancer Research Fund and the American Institute for Cancer Research Dietary Recommendations with Gut Microbiota and Inflammation Levels. (PubMed, Nutrients)
Our findings support the association of adherence to the WCRF/AICR diet with gut microbiota and inflammation. These results need to be validated in additional prospective or interventional studies.
Journal • Adherence
|
IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8)
|
IL6-L
7ms
Prognostic markers for CAR-T cell therapy in patients with relapsed/refractory multiple myeloma (IMW 2023)
Pre-infusion ALC and inflammatory markers were potential predictors of durable remission and long-term survival, and high inflammation at baseline might predispose patients to severe CRS.
Clinical • CAR T-Cell Therapy • IO biomarker
|
IL6 (Interleukin 6) • CRP (C-reactive protein)
|
IL6-L
7ms
The relationship of nutritional status with anticancer immunity and its prognostic value for head and neck cancer. (PubMed, Mol Carcinog)
In conclusion, malnutrition by PG-SGA was associated with poor prognosis in HNC patients. Based on the data of HNC patients and the 4NQO-tumor model, adequate nutritional supplementation might improve the prognosis associated with augmented anticancer immunity.
Retrospective data • Journal
|
IL6 (Interleukin 6)
|
IL6 elevation • IL6-L • IL6 expression
8ms
Postoperative Changes in Systemic Immune Tolerance Following Major Oncologic versus Minor Maxillofacial Surgery. (PubMed, Cancers (Basel))
Extensive surgery in OSCC patients is associated with a transient shift toward postoperative systemic immune tolerance compared with patients undergoing minor surgery. However, even extensive surgery causes no signs of long-lasting systemic immunosuppression. The degree of immune tolerance that occurred was associated with the duration of surgery. This supports efforts to minimize the duration of surgery.
Journal • PD(L)-1 Biomarker • IO biomarker • Surgery
|
PD-L1 (Programmed death ligand 1) • IL6 (Interleukin 6) • IL10 (Interleukin 10) • FOXP3 (Forkhead Box P3)
|
PD-L1 expression • IL6-L • IL10 overexpression • IL6 expression • FOXP3 expression
8ms
IL-6 as prognostic factor in adjuvant or metastatic skin cancer patients treated with immunotherapy: A deep biomarker analysis (ESMO 2023)
Furthermore, IL-6 is associated to higher expression of genes relate to cell cycle, proliferation and metastasis. Further investigations are needed to get additional information.
Clinical • IO biomarker • Metastases
|
EGFR (Epidermal growth factor receptor) • IL6 (Interleukin 6)
|
IL6-L • IL6 expression
8ms
EX103, a re-designed CD20xCD3 bispecific antibody, showed a favorable safety and potent single-agent antitumor activity in heavily pretreated relapsed/refractory patients with B cell non-Hodgkin lymphoma (ESMO 2023)
The preliminary Disease Control Rate (DCR) is 84.6% (11/13). Conclusions The preliminary data show favorable safety and remarkable antitumor activity, even at low doses, in heavily pretreated patients with R/R B-NHL, including those who failed prior CAR-T therapy.
Clinical
|
IL6 (Interleukin 6)
|
IL6-L
|
EX103
8ms
Association Between Pre-Treatment Circulating Immune Biomarkers And Survival In Stage III NSCLC: A Translational Analysis From NRG-RTOG 0617 (IASLC-WCLC 2023)
Higher levels of pre-treatment IL-6 were associated with worse survival in Stage III NSCLC treated with chemoradiotherapy. IL-10 may be predictive, with respect to an RT dose-effect, and deserves further study as well. K/T ratio and IL-15 levels were not prognostic or predictive.
IO biomarker
|
IL6 (Interleukin 6) • IL10 (Interleukin 10) • IL15 (Interleukin 15)
|
IL6-L
9ms
IL-6 Levels Correlate with Prognosis and Immunosuppressive Stromal Cells in Patients with Colorectal Cancer. (PubMed, Ann Surg Oncol)
Elevated serum IL-6 levels were associated with stromal IL-6 levels in CRC. High IL-6 expression in tumor-infiltrating immune cells also was associated with accumulation of immunosuppressive cells in the TME.
Journal • IO biomarker • Stroma
|
IL6 (Interleukin 6) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL10 (Interleukin 10) • FOXP3 (Forkhead Box P3)
|
IL6 elevation • IL6-L • IL6 expression • FOXP3 expression
9ms
Vitamin D Supplementation and Adherence to World Cancer Research Fund (WCRF) Diet Recommendations for Colorectal Cancer Prevention: A Nested Prospective Cohort Study of a Phase II Randomized Trial. (PubMed, Biomedicines)
Interestingly, no WCRF adherents had significantly more events if they were in the placebo (p < 0.0001), whereas no influence of WCRF was observed in the Vitamin D arm. While one-year Vitamin D supplementation might be too short to show significant preventive activity, a healthy diet and lifestyle should be the first step for preventive programs.
P2 data • Journal • Adherence
|
IL6 (Interleukin 6) • LEP (Leptin)
|
IL6-L
9ms
The Potential Effect of General Anesthetics in Cancer Surgery: Meta-Analysis of Postoperative Metastasis and Inflammatory Cytokines. (PubMed, Cancers (Basel))
In conclusion, the current evidence suggests intravenous anesthetic propofol is associated with less metastasis/recurrence and lower postoperative IL-6 level over inhaled anesthetics in the oncological surgery. We urge more well-designed clinical and preclinical studies in this field.
Retrospective data • Review • Journal • Surgery
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
|
IL6-L
10ms
ERAS Protocol Applied to Oncological Colorectal Mini-invasive Surgery Reduces the Surgical Stress Response and Improves Long-term Cancer-specific Survival. (PubMed, Surg Laparosc Endosc Percutan Tech)
ERAS protocol applied to colorectal laparoscopic surgery for cancer is able to minimize the SSR. As a possible result, cancer-specific survival seems to be improved in patients within enhanced protocols. However, even though there may be an association between an excess of SSR and worse oncological outcomes, the favorable effect of ERAS protocols toward better overall and disease-free survival is yet to be demonstrated.
Clinical protocol • Retrospective data • Journal • Surgery
|
IL6 (Interleukin 6) • CRP (C-reactive protein)
|
IL6-L
10ms
Association of Body Composition and Handgrip Strength with Interleukin-6 (IL-6) and Vitamin D Level in Cancer Patients. (PubMed, Int J Gen Med)
Cancer-associated cachexia is associated with a higher level of IL-6, lower BMI, lower fat mass index, and lower visceral fat. Vitamin D levels, but not IL-6, are correlated with muscle mass, muscle strength, and visceral fat in cancer patients.
Journal
|
IL6 (Interleukin 6)
|
IL6-L
10ms
Postoperative serum interleukin-6 levels correlate with survival in stage I-III colorectal cancer. (PubMed, BMC Gastroenterol)
Compared to CRP and PCT, the level of IL-6 was observed to be the only significant factor in predicting the prognosis of stage I-III CRC patients after surgery, and a low level of IL-6 was associated with good DFS.
Journal
|
IL6 (Interleukin 6) • CRP (C-reactive protein)
|
IL6-L
11ms
A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells. (PubMed, Front Immunol)
Pre-infusion ferritin, CRP and IL-6 were positively correlated with each peak values within the first month after infusion. Our results suggest that patients with elevated inflammation markers before CAR-T cell infusion are more likely to have poor prognosis.
Journal • CAR T-Cell Therapy • IO biomarker
|
IL6 (Interleukin 6) • CRP (C-reactive protein)
|
IL6-L
12ms
Interleukin-8 and Interleukin-6 Are Biomarkers of Poor Prognosis in Esophageal Squamous Cell Carcinoma. (PubMed, Cancers (Basel))
This enhanced growth was associated with the recruitment/accumulation of intratumoral polymorphonuclear leukocytes. In conclusion, our data suggest IL-8 as a valuable prognostic factor with potential as a biomarker for ESCC.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
|
IL6-L
1year
Effect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle Mass on Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer. (PubMed, Cancers (Basel))
In conclusion, our study supports the evidence that cachexia, with its related changes in inflammatory, body composition, and nutritional parameters, is a key prognostic and predictive factor for ICIs. Further larger studies are needed to confirm these findings and to explore the potential benefit of counteracting cachexia to improve immunotherapy efficacy.
Journal • IO biomarker • Metastases
|
IL6 (Interleukin 6)
|
IL6-L
1year
CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses. (PubMed, Science)
Mechanistically, CD5 expression by DCs was required to generate optimally protective CD5 T helper and CD8 T cells; further, deletion of CD5 from T cells dampened tumor elimination in response to ICB therapy in vivo. Thus, CD5 DCs are an essential component of optimal ICB therapy.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • CD5 (CD5 Molecule)
|
IL6-L
over1year
Probiotic effects on immunity and microbiome in HIV-1 discordant patients. (PubMed, Front Immunol)
A synbiotic intervention with L. plantarum and P. acidilactici was safe and led to small increases in CD4/CD8 ratio and minor reductions in sCD14 of uncertain clinical significance. A probiotic with the same composition was also safe but did not achieve any impact on immune parameters or faecal microbiome composition.
Clinical • Journal • Discordant
|
CD8 (cluster of differentiation 8) • IL6 (Interleukin 6)
|
IL6-L
over1year
Correlation of high serum interleukin-6 with clinical outcome and T cell response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab. (ASCO-GI 2023)
High baseline IL-6 levels can be associated with poor clinical outcomes and impaired T-cell function in patients with unresectable HCC after Ate/Bev treatment.
Clinical • Clinical data • PD(L)-1 Biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
|
IL6-L • IL6 elevation
|
Avastin (bevacizumab) • Tecentriq (atezolizumab)
over1year
High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma. (PubMed, Cancers (Basel))
High IL-6 levels were related to reduced interferon-γ and tumor necrosis factor-α production from CD8+ T cells. Overall, high baseline serum IL-6 levels were associated with worse survival outcomes and reduced T-cell responses in Pembro/Axi-treated advanced RCC patients.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
|
IL6-L • IL6 elevation
|
Keytruda (pembrolizumab) • Inlyta (axitinib)
over1year
A Quantitative Systems Pharmacology Modeling Framework for Evaluation of Cytokine Release Mediated By Intravenous Odronextamab Monotherapy in Patients with B-Cell Non-Hodgkin Lymphoma (ASH 2022)
Background Odronextamab is a hinge-stabilized, human CD20×CD3 IgG4-based bispecific antibody that binds CD20-expressing cells and CD3 on T cells, targeting CD20+ cells via T-cell-mediated cytotoxicity, independent of T-cell receptor-mediated recognition. The model was also able to predict the CD8+ T-cell and B-cell profiles over time following IV odronextamab split-dosing regimen.Conclusion This QSP model was developed to address the safety concern related to CRS following treatment with odronextamab. The work demonstrated that the QSP modeling is a powerful tool that enabled optimization of odronextamab step-up dosing to minimize the risk of higher grade (i.e. Grade 2 and 3) CRS in lymphoma patients treated with odronextamab.
Clinical
|
CD8 (cluster of differentiation 8) • IL6 (Interleukin 6)
|
CD20 expression • IL6-L
|
odronextamab (REGN1979) • T-cell receptor therapy
over1year
CIRCULATING IL-6 LEVEL IS A PROGNOSTIC BIOMARKER FOR ADVANCED HCC TREATED WITH COMBINATION IMMUNOTHERAPY (AASLD 2022)
Recently atezolizumab/bevacizumab (Atezo/Bev) combination chemotherapy regimen became the first line therapy of advanced HCC. Circulating IL-6 levels may be a novel prognostic biomarker for advanced HCC patients who underwent combination immunotherapy.
PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • CD4 (CD4 Molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • ITGAX (Integrin Subunit Alpha X) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
VEGFA elevation • CD8 expression • IL6-L • CD31 expression • IL6 expression • IL6 elevation
|
Avastin (bevacizumab) • Tecentriq (atezolizumab)
over1year
IL-6 as prognostic factor in adjuvant or metastatic skin cancer patients treated with immunotherapy - a real life study (SITC 2022)
We included pts with cutaneous squamous cell carcinoma (SCC) treated with cemiplimab (n=32), melanoma in adjuvant setting (n=61), metastatic melanoma treated with: anti-PD1 (n=103), combo ipi+nivo (n=36) and ipilimumab alone (n=32). In addition, minimum variation of IL-6 during immunotherapy are strongly associated to outcome. Further investigations are needed to get additional information.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
IL6 (Interleukin 6) • IL6R (Interleukin 6 receptor)
|
IL6-L
|
Yervoy (ipilimumab) • Libtayo (cemiplimab-rwlc)
over1year
Inflammation and Clinical Decline After Adjuvant Chemotherapy in Older Adults With Breast Cancer: Results From the Hurria Older Patients Prospective Study. (PubMed, J Clin Oncol)
In this cohort of older women with early breast cancer who were clinically fit before chemotherapy initiation, high IL-6 and CRP prechemotherapy were associated with chemotherapy-induced decline in frailty status independent of sociodemographic and clinical risk factors. Further research is needed to examine whether inflammatory markers can inform more personalized approaches to treating older breast cancer survivors.
Journal
|
IL6 (Interleukin 6) • CRP (C-reactive protein)
|
IL6-L • IL6 elevation
over1year
Probiotic Lactobacilli ameliorate alcohol-induced hepatic damage via gut microbial alteration. (PubMed, Front Microbiol)
However, the AG group showed a decreased relative abundance in this regard, confirming that LAB exerted an improvement effect on gut microbial community. These findings suggested that via gut microbiota alteration, the ingestion of LAB can alleviate the ill effects of alcohol consumption, including inflammation, liver damage, gut dysbiosis, and abnormal intestinal nutrient metabolism.
Journal
|
IL6 (Interleukin 6)
|
IL6-L
over1year
Serum levels of IL-6 and CRP can predict the efficacy of mFOLFIRINOX in patients with advanced pancreatic cancer. (PubMed, Front Oncol)
The model combining IL-6 with CRP levels helped predict the outcomes of mPC patients treated with mFOLFIRINOX (AUC: 0.811, 95%CI: 0.639-0.983, P=0.003). The serum levels of IL-6 and CRP might be considered as valuable biomarkers in predicting the outcomes of patients with mPC who received the mFOLFIRINOX regimen.
Journal
|
IL6 (Interleukin 6) • CEACAM5 (CEA Cell Adhesion Molecule 5) • CRP (C-reactive protein)
|
IL6-L • IL6 elevation
|
5-fluorouracil • irinotecan • leucovorin calcium
over1year
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers. (PubMed, J Exp Clin Cancer Res)
Nintedanib 150 mg bid is the recommended dose for combination with pembrolizumab and is currently investigated in multiple expansion cohorts. Early tumoral and circulating immune factors were associated with cancer outcome under nintedanib & pembrolizumab therapy.
Journal • Combination therapy
|
IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CCR4 (C-C Motif Chemokine Receptor 4) • CD4 (CD4 Molecule) • LAMP3 (Lysosomal Associated Membrane Protein 3) • CCL2 (Chemokine (C-C motif) ligand 2) • FOXP3 (Forkhead Box P3) • CCL22 (C-C Motif Chemokine Ligand 22) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CXCR5 (C-X-C Motif Chemokine Receptor 5)
|
IL6-L
|
Keytruda (pembrolizumab) • nintedanib